Table 4.
| Device | Alto (46) | Anaconda (40) | Aorfix (17) | Conformable (21) | Endurant II (51) | Ovation iX (42, 43) | Treovance (52, 53) | |
|---|---|---|---|---|---|---|---|---|
| Follow-up (months) | 12 | 60 | 12–60 | 12 | 12–60 | 60 | 12 | |
| Technical success rate | 100% | 98.3% | 96.3% | 100% | 99.3% | 99.7%–100% | 96% | |
| Secondary intervention | 2.7% | 21.9% | 1%–17% | 2.5% | 11% | 7.6%–20.3% | 3.5%–4.7% | |
| Mortality rate | 30-day | 0% | 1.7% | 1.8% (median of groups) | 0% | 0% | 0.3%–0.6% | 0% |
| AAA related | 0% | 2.3% | 4% in 5 years follow-up | 0% | 0.8% | 0.6%–0.7% | 0% | |
| All causes | 4% | 34.1% | 7%–31% | 3.8% | 17.7% | 21.1%–21.7% | 1.4%–6.4% | |
| Endoleaks | I | 1.3% | 5.7% | 0%–1% (combined with type III) | 0% | 0.8% | 3.1% 4.9%–6% (combined with type III) |
0.6%–1.5% |
| II | 48.3% | 22.7% | 9%–13% | 43.6% | 16.1% | 10.5%–43% | 15.3%–20.1% | |
| III | 0% | N/A | 0%–1% (combined with type I) | 0% | 0% | 0.6% 4.9–6% (combined with type I) |
0% | |
| Ruptures | 0% | 0% | 1% | 0% | 0% | 0.6% | 0% | |
| Migration (>10 mm) | 0% | 1.7% | 1–4% | 0% | 0% | 0% | 0% | |
| Limb occlusion (thrombosis or stenosis) | 0% | 7.9% | 1.83% only in year-1 | 0% | 4.2% (12 months) | 0.4%–4.3% | 0.7%–2% | |
| Aneurysm sac diameter | Reduction (>5 mm) | 21.3% | 32.4% | 42%–61% | N/A | 63.9% | 52.4%–58% | 46.3%–54.1% |
| Increase (>5 mm) | 1.6% | 6.8% | 1%–12% | 1.5% | 6% | 15.1%–15.5% | 0%–2.6% | |
*
In this table, it has been a try to summarize clinical outcomes of different endografts from different clinical studies. Note that the studies have different patient selection criteria and may differ in follow-up periods; some patients may not have HNA, and others may have been treated outside the IFU (always a minority).